Lifemd Inc is a biotechnology company focused on advancing personalized medicine by leveraging cutting-edge technology and data analytics to develop innovative diagnostic solutions and therapeutics. Their mission centers around improving patient outcomes through tailored healthcare approaches, harnessing the power of genetic information and biomarkers to better understand individual health traits and disease predispositions. By aiming to provide precise treatment options, Lifemd Inc is dedicated to transforming the landscape of healthcare and empowering patients with actionable insights for managing their health. Read More
LifeMD (NASDAQ:LFMD) reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
Chairman
KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
